{"name":"Shanghai Kechow Pharma, Inc.","slug":"shanghai-kechow-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tunlametinib plus Vemurafenib","genericName":"Tunlametinib plus Vemurafenib","slug":"tunlametinib-plus-vemurafenib","indication":"BRAF V600E-mutant melanoma","status":"phase_3"}]}],"pipeline":[{"name":"Tunlametinib plus Vemurafenib","genericName":"Tunlametinib plus Vemurafenib","slug":"tunlametinib-plus-vemurafenib","phase":"phase_3","mechanism":"This combination blocks BRAF and MEK signaling in the MAPK pathway to inhibit growth of BRAF-mutant melanoma and other cancers.","indications":["BRAF V600E-mutant melanoma","BRAF V600E-mutant non-small cell lung cancer","BRAF V600E-mutant colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9uSDlYWEpJYXdhQ2drQzhYOHJLd0twQ2Y1WE9rdGlISEk2ZngwWG9ETDNGMHpKQ2Utb0tVcGFNTGVvdEt6VjN1aWE0YWlMaThtd3l2TVdYQ3Z0cEw1RDJFZHlkZnU2WEZUMTdJdGd3ZHFzNUk?oc=5","date":"2025-10-15","type":"trial","source":"tandfonline.com","summary":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: Future Oncology: Vol 21, No 25 - tandfonline.com","headline":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPVDdrSjM3MTR5LW9qTmo1QXM0RDU1QjJRbnladkkwd3B2Nmw5QVBWRmtVZDZuVmNyVWZjb3NXOC1GNmFRUEJuUl9GYWxTSmNraGpBTU5MWUFIYnFHcTdUUS1zY0s4d1BEUWlWRGpLZm9Rb195c0owMXlNNnB4VVhqSm9tMHJXNURvNkw1QnBPXzR1TWo0OWY5RlhkbHU3N3pfcjBv?oc=5","date":"2024-05-23","type":"pipeline","source":"Yicai Global","summary":"Shanghai’s Pudong to Fast Track New Drugs, Medical Devices Onto Market - Yicai Global","headline":"Shanghai’s Pudong to Fast Track New Drugs, Medical Devices Onto Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPU2VMUFdIWmY0aDZoTC04cUhKRjU5TXlNT1B4dWtvQkZfeDRrOTA3eXZkZ1dGcEp6UkdLb2Ntcm91aXBUSGtMeEViN2lvMkt0U1c0N181NFJlOGFpNGVBRGFOU0JnY3psbDRsUG45c3g2YldHb3VSUWo4WWxuemI1UnFQTGRkbjl0a3F3VXRUNkpDTUZKak1ST3JJakNNSGk2Vnow?oc=5","date":"2024-03-19","type":"pipeline","source":"BioWorld News","summary":"China’s NMPA clears Kechow’s tunlametinib in advanced melanoma - BioWorld News","headline":"China’s NMPA clears Kechow’s tunlametinib in advanced melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1kek0wTGdXVFlNRXBySlJPd2EwS1NOaXlRQWZDRHpxSTZxV0VhQUtObU50YlBvUEZhVDJOTUcyaGFOTFdBdTdsQzhlb01KeG5UcHktYk1FT2YzMzhyZUMtU054djlfV0dSdzNDdg?oc=5","date":"2024-03-18","type":"regulatory","source":"팜뉴스","summary":"KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1 - 팜뉴스","headline":"KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Muta","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNLTlNVVZyWHdkUWhja29wZDZ1N2JkT3lITWFLVUlHTFVBWENZN1hhcFBzTXMzMHlTQ1FYdzNkU1lzNzEtcFEzSjRVa3V0ZXp1OV9YLS10QXZYRkRLQlRtZ0ZZNWdKUmZiTGhzdXhaODlIUUR6RVRhaERad1pINGM0czhRZTZEb25IbWNQaUk4UHZzMUpC?oc=5","date":"2023-09-20","type":"pipeline","source":"Frontiers","summary":"Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor - Frontiers","headline":"Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}